Chapter: Clinical Anesthesiology: Clinical Pharmacology: Adrenergic Agonists & Antagonists

Adrenergic Agonists: Dopexamine

Dopexamine, a structural analogue of DA, has potential advantages over DA because it has less β1-adrenergic (arrhythmogenic) and α-adrenergic effects.

DOPEXAMINE

Clinical Considerations

Dopexamine, a structural analogue of DA, has potential advantages over DA because it has less β₁-adrenergic (arrhythmogenic) and α-adrenergiceffects. Because of the decreased β-adrenergic effects and its specific effect on renal perfusion, it may have advantages over dobutamine. The drug has been clinically available in many countries since 1990, but has not gained widespread acceptance in practice.

Dosing & Packaging

Dopexamine infusion should be started at a rate of 0.5 mcg/kg/min, increasing to 1 mcg/kg/min at intervals of 10–15 min to a maximum infusion rate of 6 mcg/kg/min.

Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail

Clinical Anesthesiology: Clinical Pharmacology: Adrenergic Agonists & Antagonists : Adrenergic Agonists: Dopexamine |